Adult Immunization

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

Overall dyspnea was the most common symptom of long COVID in the first year after infection, according to the nationwide retrospective cohort study.

One study showed the boosters provide significant protection against hospitalization and ED care and the other found vaccine effectiveness of 84% in older adults.

The vaccination campaign in the US also has prevented more than 18 million hospitalizations and saved $1 trillion in medical costs, according to a modeling study.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.

Confidence in vaccines is lower post-pandemic across all demographic groups and is not limited to traditional "anti-vaxxers," say authors of a new study.

The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.

The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.

Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.

AAFP Board Chair Sterling Ransone, Jr, MD, encourages patients to get both shots at one visit; if they don't, he has strategies to bring them back for the one they didn't get.

AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.

Vaccine fatigue in the US, says Vanderbilt University's William Schaffner, MD, is plentiful for vaccines that are are good—but not perfect.

Let's call the next round of COVID-19 shots "updated vaccines," and help the public understand the true role of this vaccination, says NFID's Schaffner.